0000000001122736

AUTHOR

Luqi Wang

showing 2 related works from this author

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: A randomized trial

2009

BACKGROUND: Low-dose oral vitamin K decreases the international normalized ratio (INR) in overanticoagulated patients who receive warfarin therapy. Its effects on bleeding events are uncertain. OBJECTIVE: To see whether low-dose oral vitamin K reduces bleeding events over 90 days in patients with warfarin-associated coagulopathy. DESIGN: Multicenter, randomized, placebo-controlled trial. Randomization was computer-generated, and participants were allocated to trial groups by using sequentially numbered study drug containers. Patients, caregivers, and those who assessed outcomes were blinded to treatment assignment. SETTING: 14 anticoagulant therapy clinics in Canada, the United States, and …

Malemedicine.medical_specialtyRandomizationVitamin Kmedicine.drug_classAdministration OralHemorrhageoral vitamin k anticoagulantsPlacebolaw.inventionSettore MED/15 - Malattie Del SanguePlacebosRandomized controlled trialOral administrationlawInternal medicineThromboembolismInternal MedicinemedicineOutpatient clinicHumansInternational Normalized RatioAgedAged 80 and overbusiness.industryAnticoagulantWarfarinAge FactorsAnticoagulantsGeneral MedicineMiddle AgedAntifibrinolytic AgentsSurgeryClinical trialTreatment OutcomeFemaleWarfarinbusinessmedicine.drug
researchProduct

Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10

2009

SummaryUnanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

Malemedicine.medical_specialtyVitamin Kmedicine.drug_classAdministration OralHemorrhagePharmacotherapyInternal medicinemedicineCoagulopathyHumansInternational Normalized RatioProspective StudiesProspective cohort studyAgedAged 80 and overVenous ThrombosisVascular diseasebusiness.industryAnticoagulantWarfarinAnticoagulantsHematologyMiddle Agedmedicine.diseaseThrombosisSurgeryFemaleINR oral anticoagulantsWarfarinbusinessFollow-Up Studiesmedicine.drugCohort studyThrombosis and Haemostasis
researchProduct